9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma

PHASE2WithdrawnINTERVENTIONAL

Timeline

Start Date

December 18, 2030

Primary Completion Date

June 18, 2033

Study Completion Date

June 18, 2034

Conditions

Salivary Gland CarcinomaAdenoid Cystic CarcinomaSalivary Gland CancerSalivary Gland Neoplasms

Interventions

DRUG

9-ING-41

15 mg/kg as intravenous infusion on Days 1 and Day 4 of a 21-day cycle

DRUG

Carboplatin

Carboplatin AUC 5 intravenously on Day 1 of a 21-day cycle

Trial Locations (1)

Dana-Farber Cancer Institute, Boston